The interconnected development of artificial intelligence, quantum computing, advanced networking, robotics, biotechnology, and related fields has ushered in what I refer to as the Acceleration Era of technological convergence. Healthcare and medical research are the areas where this convergence will have the greatest human impact.

Today, AI is already changing discovery pipelines and clinical workflows. Computing, sensing, and secure communications are examples of quantum technologies that are quickly progressing from laboratory proof-of-concept into early clinical and research applications. When combined, they unlock potential that traditional systems are unable to.

The 21st century is the century of biology, accelerated by physics and artificial intelligence, as I highlighted in a previous Forbes article on future medicine https://www.forbes.com/sites/chuckbrooks/2024/10/22/future-medicine-physics-biology-and-ai-will-transform-human-health/

The Human Genome Project was merely the beginning. The workhorses of both health and illness are proteins. The fundamental stages of therapeutic development continue to identify disease-associated proteins, figuring out their structures, locating binders (drug candidates), and testing them.

The number of drug-like small-molecule chemotypes that humans have synthesized is less than 10 million, whereas the theoretical chemical space is in the decillions. This presents challenges for both traditional AI and classical trial-and-error. There is no way to explore using brute force. Instead of discovering truly novel chemistry, pure AI trained on existing data frequently rediscovers variations of known compounds. It has long been computationally difficult to accurately model how a drug molecule interacts with a protein in water using quantum physics.

That is shifting. The design of never-before-seen molecules and more accurate predictions of binding prior to laboratory synthesis are made possible by hybrid quantum-classical approaches and developments in quantum-informed modeling, such as platforms that integrate Deep Quantum Modeling. Thereafter, AI can refine those candidates based on physics.

The outcome is a route toward treating many more of the approximately 10,000 “druggable” proteins linked to human disease, not just the few hundred for which there are currently approved treatments. This is important for precision intervention in rare conditions, cancer, chronic diseases, and new infectious threats.

AI’s Immediate and Expanding Footprint

In the areas of operations, drug discovery, personalized medicine, and diagnostics, AI already provides quantifiable benefits. To enhance detection accuracy, forecast treatment response, and facilitate risk stratification, multimodal systems combine imaging, genomics, electronic health records, and other data.

Protein structure prediction and candidate identification have been expedited by generative models and tools like AlphaFold; FDA applications involving AI-discovered components have surpassed 300 recently, with companies like Isomorphic Labs advancing AI-designed immunology and oncology candidates toward human trials.

Multi-step care pathways are being streamlined, and patient-specific outcomes are being simulated by digital twins and agentic systems. Predictive analytics optimizes hospital logistics and resource allocation, while administrative automation lessens the workload for clinicians.

According to a World Economic Forum analysis, the AI-in-healthcare market is expected to reach $491 billion by 2032, growing at a rate of about 43% per year. Quantum vs AI in healthcare: How they differ and why leaders must prepare for convergence | World Economic Forum

These gains are genuine and expand rapidly. However, the full complexity of molecular interactions, ultra-early disease signals, and the highest-dimensional multi-omics datasets continue to be challenges for classical computing.

Quantum Technologies Bridge the Divide—With Real Advancement

These gaps are precisely filled by quantum sensing, communication, and computing. The transition from theory to early practice is demonstrated by specific institutional examples:

• Protein-ligand complexes of up to 12,635 atoms, including trypsin and T4-lysozyme in explicit solvent, have been simulated by IBM, Cleveland Clinic, and RIKEN using quantum-centric supercomputing. This shows a workable hybrid workflow for drug-discovery-relevant chemistry and represents the largest biologically significant molecular simulations carried out with quantum hardware to date—a roughly 40-fold increase in system size over previous benchmarks. Cleveland Clinic, RIKEN, and IBM Model a 12,635-Atom Protein – the Largest Known to Be Simulated with Quantum Computers

• By showcasing end-to-end quantum-classical simulation of critical processes in photodynamic therapy for cancer on actual quantum hardware, Algorithmiq’s partnership with Cleveland Clinic and IBM won the Wellcome Leap Quantum for Bio (Q4Bio) How IBM Quantum is enabling healthcare and biology research | IBM Quantum Computing Blog

• The Mayo Clinic has been investigating and developing magnetocardiography (MCG), a method that detects the magnetic fields of the heart with high sensitivity for ischemia, arrhythmias, and related conditions using quantum sensors (such as SQUID and newly developed optically pumped magnetometers). Its potential as a non-invasive adjunct for cardiac triage and cardiomyopathy screening is highlighted by recent clinical evaluations and studies conducted by Mayo investigators. 281 Use of Magnetocardiography in the Emergency Department for Diagnosis of Cardiac Ischemia in Acute Chest Pain Patients - Annals of Emergency Medicine

• Using up to 80–156 qubits, Moderna and IBM have used hybrid quantum-classical variational algorithms (including CVaR-based approaches) on IBM Heron processors to predict the secondary structure of mRNA sequences up to 60 nucleotides—the longest such folding patterns simulated on quantum hardware to date. The design of mRNA vaccines and treatments is directly supported by this IBM Quantum Moderna case study; related IEEE and follow-on work. Moderna and IBM use quantum computing to model mRNA | IBM Quantum Computing Blog

• In partnership with the University of Toronto, Insilico Medicine, and other institutions, researchers at St. Jude Children’s Research Hospital created a hybrid quantum-classical generative model that generated KRAS inhibitor candidates with experimental validation. The first experimental validation of quantum-generated hits in this context was reported when two of the fifteen synthesized molecules demonstrated promising binding and cellular activity against this traditionally “undruggable” cancer driver. Quantum computing makes waves in drug discovery | St. Jude Research

According to published studies, quantum machine-learning enhancements of pathology AI have also classified breast cancer subtypes with accuracy comparable to classical models, using about 50% less data and operating about 25 times faster. While quantum communication initiatives seek to safeguard AI pipelines and electronic health records, quantum sensors in general allow for the early detection of biomarkers.

The combination offers the most leverage. Quantum provides physics-accurate simulation and sensing that classical AI cannot fully replicate; AI optimizes quantum circuits, interprets results, and coordinates hybrid pipelines.

When combined with quantum simulation, agentic AI can create closed-loop discovery systems that generate hypotheses, simulate at the molecular level, assess, and repeat. When combined with explainable AI methods, the approach improves interpretability and speeds up drug design, biomarker discovery, and personalized treatment modeling.

The same convergence can optimize supply chains, logistics, and ICU allocation from an operational standpoint. Quantum-enhanced analysis of heterogeneous population-scale datasets from a systems perspective reveals stronger correlations between multi-omics and clinical data.

Opportunities, Risks, and the Imperative for Preparation

Faster and more effective treatment discovery, earlier intervention that improves outcomes and reduces long-term costs, truly individualized care, and a more robust digital health infrastructure are all potentially revolutionary.

Short-term advancements will be hybrid and domain-specific, starting with sensing and specific simulation tasks and expanding to a wider quantum advantage as error-corrected systems advance. In the medium term, we can expect further integration into precision-medicine platforms.

However, every potent technology has a drawback. Healthcare settings are already under stress, and AI adds new cybersecurity risks. While quantum computing provides new tools for defense, it also poses a threat to current cryptography. Critical issues still include workforce skills, algorithmic bias, data privacy, regulatory validation, and fair access.

Investments in quantum-safe cybersecurity, institutional experience-building pilot programs, and upskilling encompassing AI, quantum literacy, and clinical domain knowledge are imperative for leaders. Traditional silos are no longer adequate, and professional development and higher education must adjust to this convergence.

There is no longer any doubt about the Quantum Frontier Era. Advances in 2025 and 2026 have brought quantum technologies closer to being useful. Together with the quick development of AI, we are at a turning point in medical research and healthcare.

Organizations and societies that make careful preparations, striking a balance between ambition and strict validation, security, and ethics, will create a future where illness is identified earlier, treatments are more accurate, and human life expectancy increases. Waiting puts one at risk of falling behind the Acceleration Era itself. The route is neither simple nor certain. However, the path forward is evident: intelligent computation, biology, and physics are coming together to transform